RESUMO
This study was designed to explore the potential mechanisms of electroacupuncture (EA) in treating inflammatory bowel disease- (IBD-) related anxiety and mood disorders. A colitis model was induced in rats with 2, 4, 6-trinitrohydrosulfonic acid (TNBS), followed by ST36 and SP6 targeted therapy by EA or sham EA treatment. The elevated plus maze (EPM) and open-field test (OFT) were performed to assess the state of anxiety and depression-like behavior. Tests were carried out by 16S rDNA amplification sequence, 1H nuclear magnetic resonance (1H NMR) spectroscopy, immunofluorescence staining, and enzyme-linked immunosorbent assay (ELISA). The analyses detailed metabolic alterations and the Toll-like receptor 4 (TLR4) signaling pathway/NOD-like receptor protein 3 (NLRP3) inflammasome in rats' hippocampal region. Furthermore, the activity of the hypothalamic-pituitary adrenal (HPA) axis and gut microbiome was assessed. As a result of treatment, EA significantly improved in the behavioral tests and altered the composition of the gut microbiome through a significant increase in the density of short chain fatty acids (SCFAs) producers mainly including Ruminococcaceae, Phascolarctobacterium, and Akkermansiaceae. EA upregulated the metabolites of the hippocampus mainly containing l-glutamine and gamma-aminobutyric acid (GABA), as well as ZO-1 expression. Whereas the treatment blocked the TLR4/nuclear factor- kappa B (NF-κB) signaling pathways and NLRP3 inflammasomes, along with downregulating the interleukin- (IL-) 1ß level. The hyperactivity of the HPA axis was also diminished. In conclusion, EA at ST36 and SP6 attenuated anxiety and depression-like behavior in colitis model rats through their effects on the gut microbiome by modulating the hippocampal inflammatory response and metabolic disorders, as well as the HPA axis. This study provides evidence for clinical application of EA to serve as an adjunctive treatment for IBD-related anxiety and depression.
Assuntos
Ansiedade/terapia , Encefalopatias Metabólicas/fisiopatologia , Depressão/terapia , Eletroacupuntura/métodos , Hipocampo/fisiopatologia , Inflamação/fisiopatologia , Doenças Inflamatórias Intestinais/terapia , Animais , Masculino , Ratos , Ratos Sprague-DawleyAssuntos
Encefalopatias Metabólicas/tratamento farmacológico , Encéfalo/efeitos dos fármacos , Creatina/metabolismo , Metabolismo Energético/efeitos dos fármacos , Glicina/análogos & derivados , Guanidinoacetato N-Metiltransferase/metabolismo , Proteínas de Membrana Transportadoras/metabolismo , Animais , Encéfalo/enzimologia , Encéfalo/fisiopatologia , Encefalopatias Metabólicas/enzimologia , Encefalopatias Metabólicas/fisiopatologia , Glicina/metabolismo , Glicina/uso terapêutico , HumanosRESUMO
Women with persistent vomiting during pregnancy need early referral to appropriate health facilities. Delayed referral and inappropriate management may lead to metabolic encephalopathy from a variety of causes, including electrolyte derangements or thiamine deficiency (Wernicke's encephalopathy) (WE). We present a case of persistent vomiting in pregnancy in which there was delayed referral, inappropriate treatment and failure to associate neurological signs such as terminal neck stiffness with WE, resulting in poor fetomaternal outcomes. In this report, we discuss the following lessons: (i) the need for early transfer of a patient with persistent vomiting and enigmatic clinical features to a higher healthcare facility; (ii) failure to associate neurological signs with complications of hyperemesis gravidarum/WE; (iii) lack of thiamine supplementation; and (iv) the advantages of magnetic resonance imaging over a computed tomography scan in the diagnosis of WE.
Assuntos
Diagnóstico Tardio , Hiperêmese Gravídica/complicações , Encefalopatia de Wernicke , Adulto , Encefalopatias Metabólicas/diagnóstico , Encefalopatias Metabólicas/etiologia , Encefalopatias Metabólicas/fisiopatologia , Encefalopatias Metabólicas/terapia , Tomada de Decisão Clínica , Diagnóstico Tardio/efeitos adversos , Diagnóstico Tardio/prevenção & controle , Diagnóstico Diferencial , Evolução Fatal , Feminino , Humanos , Imageamento por Ressonância Magnética/métodos , Gravidez , Resultado da Gravidez , Respiração Artificial/métodos , Tempo para o Tratamento , Tomografia Computadorizada por Raios X/métodos , Encefalopatia de Wernicke/diagnóstico , Encefalopatia de Wernicke/etiologia , Encefalopatia de Wernicke/fisiopatologia , Encefalopatia de Wernicke/terapiaAssuntos
Acidose/etiologia , Encefalopatias Metabólicas/etiologia , Hiperamonemia/etiologia , Derivação Urinária/efeitos adversos , Acidose/fisiopatologia , Idoso , Amônia/farmacocinética , Encefalopatias Metabólicas/fisiopatologia , Carcinoma de Células de Transição/cirurgia , Proteínas Alimentares/administração & dosagem , Proteínas Alimentares/farmacocinética , Epilepsia Parcial Complexa/etiologia , Feminino , Humanos , Concentração de Íons de Hidrogênio , Hiperamonemia/dietoterapia , Hiperamonemia/fisiopatologia , Absorção Intestinal , Proteínas de Vegetais Comestíveis/administração & dosagem , Neoplasias da Bexiga Urinária/cirurgiaRESUMO
BACKGROUND: Metabolic treatment in glutaric aciduria type I (GA-I) including a low lysine diet with lysine-free, tryptophan-reduced amino acid supplements (AAS), carnitine supplementation and early start of emergency treatment during putatively threatening episodes of intermittent febrile illness dramatically improves the outcome and thus has been recommended by an international guideline group (Kölker et al, J Inherit Metab Dis 30:5-22, 2007). However, possible affection of linear growth, weight gain and biochemical follow-up monitoring has not been studied systematically. METHODS: Thirty-three patients (n = 29 asymptomatic, n = 4 dystonic) with GA-I who have been identified by newborn screening in Germany from 1999 to 2009 were followed prospectively during the first six years of life. Dietary treatment protocols, anthropometrical and biochemical parameters were longitudinally evaluated. RESULTS: Mean daily intake as percentage of guideline recommendations was excellent for lysine (asymptomatic patients: 101 %; dystonic patients: 103 %), lysine-free, tryptophan-reduced AAS (108 %; 104 %), energy (106 %; 110 %), and carnitine (92 %; 102 %). Low lysine diet did not affect weight gain (mean SDS 0.05) but mildly impaired linear growth in asymptomatic patients (mean SDS -0.38), while dystonic patients showed significantly reduced weight gain (mean SDS -1.32) and a tendency towards linear growth retardation (mean SDS -1.03). Patients treated in accordance with recent recommendations did not show relevant abnormalities of routine biochemical follow-up parameters. INTERPRETATION: Low lysine diet promotes sufficient intake of essential nutrients and anthropometric development in asymptomatic children up to age 6 year, whereas individualized nutritional concepts are required for dystonic patients. Revised recommendations for biochemical monitoring might be required for asymptomatic patients.
Assuntos
Erros Inatos do Metabolismo dos Aminoácidos/dietoterapia , Pesos e Medidas Corporais , Encefalopatias Metabólicas/dietoterapia , Alimentos Formulados , Glutaril-CoA Desidrogenase/deficiência , Lisina/administração & dosagem , Erros Inatos do Metabolismo dos Aminoácidos/sangue , Erros Inatos do Metabolismo dos Aminoácidos/metabolismo , Erros Inatos do Metabolismo dos Aminoácidos/fisiopatologia , Antropometria , Biomarcadores/análise , Biomarcadores/sangue , Encefalopatias Metabólicas/sangue , Encefalopatias Metabólicas/metabolismo , Encefalopatias Metabólicas/fisiopatologia , Carnitina/administração & dosagem , Criança , Pré-Escolar , Suplementos Nutricionais , Ingestão de Alimentos/fisiologia , Feminino , Seguimentos , Glutaril-CoA Desidrogenase/sangue , Glutaril-CoA Desidrogenase/metabolismo , Humanos , Lactente , Masculino , Monitorização Fisiológica/métodosRESUMO
Eleven infants who were fed a thiamine-deficient formula for a mean of 3 months were evaluated for immediate and long-term auditory abnormalities. At presentation, 8 infants had auditory neuropathy spectrum disorder (ANSD), which resolved with supplementary thiamine in 5 children, was permanent in 2 children, and deteriorated in 1 patient who died at the age of 7 years. An additional patient had an auditory pattern corresponding to that of auditory neuropathy of brain stem origin. The 2 remaining patients had unilateral cochlear hearing loss. Six to 8 years later, all patients with transient ANSD had normal audiograms, 2 patients had unilateral cochlear hearing loss, and the rest had neural hearing loss. All survivors had a language developmental delay and impaired speech intelligibility of varying degrees, especially in the presence of background noise. Thiamine is crucial for normal auditory development and function, and its deficiency may be considered an acquired metabolic cause of ANSD in infants.
Assuntos
Encefalopatias Metabólicas/etiologia , Perda Auditiva Central/etiologia , Fórmulas Infantis , Transtornos da Nutrição do Lactente/complicações , Deficiência de Tiamina/complicações , Audiometria de Tons Puros , Encefalopatias Metabólicas/fisiopatologia , Tronco Encefálico/fisiopatologia , Potenciais Evocados Auditivos do Tronco Encefálico/fisiologia , Feminino , Seguimentos , Perda Auditiva Central/diagnóstico , Perda Auditiva Central/fisiopatologia , Humanos , Lactente , Transtornos da Nutrição do Lactente/fisiopatologia , Transtornos do Desenvolvimento da Linguagem/diagnóstico , Transtornos do Desenvolvimento da Linguagem/etiologia , Transtornos do Desenvolvimento da Linguagem/fisiopatologia , Masculino , Tempo de Reação/fisiologia , Deficiência de Tiamina/fisiopatologiaRESUMO
Organic acidurias or organic acidemias constitute a group of inherited disorders caused by deficient activity of specific enzymes of amino acids, carbohydrates or lipids catabolism, leading to large accumulation and excretion of one or more carboxylic (organic) acids. Affected patients usually present neurologic symptoms and abnormalities, sometimes accompanied by cardiac and skeletal muscle alterations, whose pathogenesis is poorly known. However, in recent years growing evidence has emerged indicating that mitochondrial dysfunction is directly or indirectly involved in the pathology of various organic acidemias. Mitochondrial impairment in some of these diseases are generally due to mutations in nuclear genes of the tricarboxylic acid cycle or oxidative phosphorylation, while in others it seems to result from toxic influences of the endogenous organic acids to the mitochondrion. In this minireview, we will briefly summarize the present knowledge obtained from human and animal studies showing that disruption of mitochondrial homeostasis may represent a relevant pathomechanism of tissue damage in selective organic acidemias. The discussion will focus on mitochondrial alterations found in patients affected by organic acidemias and by the deleterious effects of the accumulating organic acids on mitochondrial pathways that are crucial for ATP formation and transfer. The elucidation of the mechanisms of toxicity of these acidic compounds offers new perspectives for potential novel adjuvant therapeutic strategies in selected disorders of this group.
Assuntos
Trifosfato de Adenosina/metabolismo , Ácidos Carboxílicos/metabolismo , Homeostase/fisiologia , Erros Inatos do Metabolismo/fisiopatologia , Mitocôndrias/fisiologia , Doenças Mitocondriais/fisiopatologia , Acetil-CoA C-Aciltransferase/deficiência , Erros Inatos do Metabolismo dos Aminoácidos/fisiopatologia , Animais , Síndrome de Barth/fisiopatologia , Encefalopatias Metabólicas/fisiopatologia , Encefalopatias Metabólicas Congênitas/fisiopatologia , Glutaril-CoA Desidrogenase/deficiência , Humanos , Mitocôndrias/metabolismo , Acidemia Propiônica/fisiopatologia , Púrpura/fisiopatologiaRESUMO
We report 4 children with late-onset (type III) multiple acyl-CoA dehydrogenase deficiency, also known as glutaric aciduria type II, which is an autosomal recessive disorder of fatty acid and amino acid metabolism. The underlying deficiency is in the electron transfer flavoprotein or electron flavoprotein dehydrogenase. Clinical presentations include fatal acute neonatal metabolic encephalopathies with/without organ system anomalies (types I and II) and late-onset acute metabolic crises, myopathy, or neurodevelopmental delays (type III). Two patients were identified in childhood following a metabolic crisis and/or neurodevelopmental delay, and 2 were identified by newborn metabolic screening. Our cases will illustrate the difficulty in making a biochemical diagnosis of late-onset (type III) multiple acyl-CoA dehydrogenase deficiency from plasma acylcarnitines and urine organic acids in both symptomatic and asymptomatic children. However, they emphasize the need for timely diagnosis to urgently implement prophylactic treatment for life-threatening metabolic crises with low protein/fat diets supplemented with riboflavin and carnitine.
Assuntos
Deficiência Múltipla de Acil Coenzima A Desidrogenase/diagnóstico , Deficiência Múltipla de Acil Coenzima A Desidrogenase/fisiopatologia , Encefalopatias Metabólicas/diagnóstico , Encefalopatias Metabólicas/fisiopatologia , Encefalopatias Metabólicas/terapia , Carnitina/análogos & derivados , Carnitina/análise , Carnitina/sangue , Criança , Pré-Escolar , Deficiências do Desenvolvimento/diagnóstico , Deficiências do Desenvolvimento/fisiopatologia , Deficiências do Desenvolvimento/terapia , Feminino , Humanos , Masculino , Programas de Rastreamento , Doenças Metabólicas/diagnóstico , Doenças Metabólicas/fisiopatologia , Doenças Metabólicas/terapia , Deficiência Múltipla de Acil Coenzima A Desidrogenase/terapiaRESUMO
Mitochondrial dysfunction hypothetically contributes to neuronal degeneration in patients with Parkinson's disease. While several in vitro data exist, the measurement of cerebral mitochondrial dysfunction in living patients with Parkinson's disease is challenging. Anatomical magnetic resonance imaging combined with phosphorus and proton magnetic resonance spectroscopic imaging provides information about the functional integrity of mitochondria in specific brain areas. We measured partial volume corrected concentrations of low-energy metabolites and high-energy phosphates with sufficient resolution to focus on pathology related target areas in Parkinson's disease. Combined phosphorus and proton magnetic resonance spectroscopic imaging in the mesostriatal region was performed in 16 early and 13 advanced patients with Parkinson's disease and compared to 19 age-matched controls at 3 Tesla. In the putamen and midbrain of both Parkinson's disease groups, we found a bilateral reduction of high-energy phosphates such as adenosine triphophosphate and phosphocreatine as final acceptors of energy from mitochondrial oxidative phosphorylation. In contrast, low-energy metabolites such as adenosine diphophosphate and inorganic phosphate were within normal ranges. These results provide strong in vivo evidence that mitochondrial dysfunction of mesostriatal neurons is a central and persistent phenomenon in the pathogenesis cascade of Parkinson's disease which occurs early in the course of the disease.
Assuntos
Encefalopatias Metabólicas/metabolismo , Encéfalo/metabolismo , Metabolismo Energético/fisiologia , Mitocôndrias/metabolismo , Doenças Mitocondriais/metabolismo , Doença de Parkinson/metabolismo , Trifosfato de Adenosina/análise , Trifosfato de Adenosina/metabolismo , Idoso , Biomarcadores/análise , Biomarcadores/metabolismo , Encéfalo/fisiopatologia , Química Encefálica/fisiologia , Encefalopatias Metabólicas/diagnóstico , Encefalopatias Metabólicas/fisiopatologia , Progressão da Doença , Feminino , Humanos , Espectroscopia de Ressonância Magnética/métodos , Masculino , Pessoa de Meia-Idade , Doenças Mitocondriais/diagnóstico , Doenças Mitocondriais/fisiopatologia , Fosforilação Oxidativa , Doença de Parkinson/diagnóstico , Doença de Parkinson/fisiopatologia , Fosfocreatina/análise , Fosfocreatina/metabolismo , Fósforo/metabolismo , Valor Preditivo dos Testes , Prótons , Putamen/metabolismo , Putamen/fisiopatologia , Substância Negra/metabolismo , Substância Negra/fisiopatologiaRESUMO
The mechanism of the abnormal increase in extracellular glutamate concentration in the hippocampus induced with 100mM KCl in zinc deficiency is unknown. In the present study, the changes in glutamate release (exocytosis) and GLT-1, a glial glutamate transporter, expression were studied in young rats fed a zinc-deficient diet for 4 weeks. Exocytosis at mossy fiber boutons was enhanced as reported previously and GLT-1 protein was increased in the hippocampus. The enhanced exocytosis is thought to increase extracellular glutamate concentration. However, the basal concentration of extracellular glutamate in the hippocampus was not increased by zinc deficiency, suggesting that GLT-1 protein increased serves to maintain the basal concentration of extracellular glutamate. The enhanced exocytosis was attenuated in the presence of 100microM ZnCl(2), which attenuated the abnormal increase in extracellular glutamate induced with high K(+) in zinc deficiency. The present study indicates that zinc attenuates abnormal glutamate release in zinc deficiency. The enhanced exocytosis was also attenuated in slices from zinc-deficient rats administered Yokukansan, a herbal medicine, in which the abnormal increase in extracellular glutamate induced with high K(+) was attenuated. It is likely that Yokukansan is useful for prevention or cure of abnormal glutamate release. The enhanced exocytosis in zinc deficiency is a possible mechanism on abnormal increase in extracellular glutamate in the hippocampus induced with high K(+).
Assuntos
Encefalopatias Metabólicas/metabolismo , Medicamentos de Ervas Chinesas/farmacologia , Ácido Glutâmico/metabolismo , Hipocampo/metabolismo , Transmissão Sináptica/fisiologia , Zinco/deficiência , Animais , Encefalopatias Metabólicas/tratamento farmacológico , Encefalopatias Metabólicas/fisiopatologia , Cloretos/farmacologia , Endocitose/efeitos dos fármacos , Endocitose/fisiologia , Transportador 2 de Aminoácido Excitatório/efeitos dos fármacos , Transportador 2 de Aminoácido Excitatório/metabolismo , Líquido Extracelular/efeitos dos fármacos , Líquido Extracelular/metabolismo , Hipocampo/efeitos dos fármacos , Hipocampo/fisiopatologia , Hiperpotassemia/induzido quimicamente , Hiperpotassemia/metabolismo , Hiperpotassemia/fisiopatologia , Masculino , Fibras Musgosas Hipocampais/efeitos dos fármacos , Fibras Musgosas Hipocampais/metabolismo , Técnicas de Cultura de Órgãos , Potássio/metabolismo , Terminações Pré-Sinápticas/efeitos dos fármacos , Terminações Pré-Sinápticas/metabolismo , Ratos , Ratos Wistar , Transmissão Sináptica/efeitos dos fármacos , Zinco/farmacologia , Compostos de Zinco/farmacologiaRESUMO
Aging is a complex biological phenomenon which involves free radicals and oxidative stress. Brain is more susceptible and vulnerable to oxidative damage due to its high-polyunsaturated fatty acid content and high rate of aerobic metabolism. Since the antioxidant defense system is diminished during aging, antioxidant supplementation might be a protective strategy against age-associated oxidative damage. The present study evaluates the antioxidant potential of (-)-epigallocatechin-3-gallate (EGCG), a major polyphenol present in green tea against age-associated oxidative damage in rat brain. Male albino rats of Wistar strain were used in the study. Group I (young) and Group II (aged) rats received saline alone orally for 30 days. Group III (young) and Group IV (aged) rats received EGCG (2mg/kg body weight/day) orally for 30 days. Antioxidant status and oxidative damage were assessed. EGCG brought about an augmentation in the activities of enzymic antioxidants like superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glucose-6-phosphate dehydrogenase and improved the non-enzymic antioxidants like tocopherol, ascorbic acid and glutathione. EGCG ameliorated the malondialdehyde and protein carbonyl levels. Thus, EGCG has emerged out as a good antioxidant neutraceutical and a neuroprotective agent in alleviating the age-associated oxidative damage in aged rat brain.
Assuntos
Envelhecimento/metabolismo , Encefalopatias Metabólicas/metabolismo , Catequina/análogos & derivados , Citoproteção/fisiologia , Fármacos Neuroprotetores/farmacologia , Estresse Oxidativo/fisiologia , Envelhecimento/efeitos dos fármacos , Animais , Antioxidantes/metabolismo , Antioxidantes/farmacologia , Encefalopatias Metabólicas/tratamento farmacológico , Encefalopatias Metabólicas/fisiopatologia , Catequina/farmacologia , Citoproteção/efeitos dos fármacos , Flavonoides/farmacologia , Peroxidação de Lipídeos/efeitos dos fármacos , Peroxidação de Lipídeos/fisiologia , Masculino , Degeneração Neural/tratamento farmacológico , Degeneração Neural/metabolismo , Degeneração Neural/fisiopatologia , Estresse Oxidativo/efeitos dos fármacos , Fenóis/farmacologia , Polifenóis , Ratos , Ratos Wistar , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/fisiologiaRESUMO
A study of complex I (NADH:ubiquinone oxidoreductase) activity in Parkinson's disease (PD) brain has identified loss of activity only in substantia nigra although loss of activity of this enzyme has been identified in a number of non-brain tissues. We investigated this paradox by studying complex I and other complexes of the mitochondrial electron transport chain in frontal cortex from PD and aged control brain using a variety of assay conditions and tissue preparations. We found increasingly significant losses of complex I activity in PD frontal cortex as increasingly pure mitochondria were studied. Complexes II, III, and IV were comparable in PD and controls. Inclusion of bovine serum albumin in the assay increased enzyme activity but lessened discrimination between PD and controls. Complex I deficiency in PD brain is not confined to substantia nigra. Methodological issues are critical in demonstrating this loss of activity.
Assuntos
Encefalopatias Metabólicas/metabolismo , Complexo I de Transporte de Elétrons/deficiência , Lobo Frontal/metabolismo , Doenças Mitocondriais/complicações , Doenças Mitocondriais/metabolismo , Doença de Parkinson/metabolismo , Idoso , Idoso de 80 Anos ou mais , Bioensaio/métodos , Bioensaio/normas , Biomarcadores/análise , Biomarcadores/metabolismo , Encefalopatias Metabólicas/fisiopatologia , Metabolismo Energético/fisiologia , Lobo Frontal/fisiopatologia , Histocitoquímica/métodos , Histocitoquímica/normas , Humanos , Mitocôndrias/metabolismo , Doenças Mitocondriais/fisiopatologia , Neurônios/metabolismo , Doença de Parkinson/fisiopatologia , Valor Preditivo dos Testes , alfa-Sinucleína/genética , alfa-Sinucleína/metabolismoRESUMO
Emerging epidemiological data indicates that diabetes is a potential predisposing factor for neuropsychiatric deficits as stroke, cerebrovascular diseases, diabetic encephalopathy, depression and anxiety. Diabetic encephalopathy, characterized by impaired cognitive functions and neurochemical and structural abnormalities, involves direct neuronal damage caused by intracellular glucose. Curcumin, a well-established phenolic antioxidant and anti-inflammatory molecule, is capable of playing an important role against amyloid and dendritic pathology and thus has neuroprotective properties. The aim of the present study was to explore the effect of curcumin (60 mg/kg; p.o.) on cognitive functions, oxidative stress and inflammation in diabetic rats. Learning and memory behaviors were investigated using a spatial version of the Morris water maze test. Acetylcholinesterase activity, a marker of cholinergic dysfunction, was increased by 80% in the cerebral cortex of diabetic rats. There was 107% and 121% rise in thiobarbituric acid reactive substance levels in cerebral cortex and hippocampus of diabetic rats, respectively. Reduced glutathione level and enzymatic activities of superoxide dismutase and catalase were decreased in both cerebral cortex and hippocampal regions of diabetic rat brain. Nitrite levels in cerebral cortex and hippocampus were increased by 112% and 94% respectively. Serum TNF-alpha, a marker for inflammation, was found to increase by 1100% in diabetic rats. Chronic treatment with curcumin (60 mg/kg; p.o.) significantly attenuated cognitive deficit, cholinergic dysfunction, oxidative stress and inflammation in diabetic rats. The results emphasize the involvement of cholinergic dysfunction, oxidative stress and inflammation in the development of cognitive impairment in diabetic animals and point towards the potential of curcumin as an adjuvant therapy to conventional anti-hyperglycemic regimens for the prevention and treatment of diabetic encephalopathy.
Assuntos
Encefalopatias Metabólicas/tratamento farmacológico , Transtornos Cognitivos/tratamento farmacológico , Curcumina/uso terapêutico , Diabetes Mellitus Experimental/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Fármacos Neuroprotetores/uso terapêutico , Acetilcolinesterase/metabolismo , Animais , Comportamento Animal/efeitos dos fármacos , Encefalopatias Metabólicas/etiologia , Encefalopatias Metabólicas/fisiopatologia , Catalase/metabolismo , Córtex Cerebral/metabolismo , Transtornos Cognitivos/etiologia , Transtornos Cognitivos/fisiopatologia , Complicações do Diabetes/tratamento farmacológico , Complicações do Diabetes/fisiopatologia , Diabetes Mellitus Experimental/fisiopatologia , Glutationa/metabolismo , Hipocampo/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Aprendizagem em Labirinto/efeitos dos fármacos , Memória/efeitos dos fármacos , Nitritos/metabolismo , Ratos , Ratos Wistar , Superóxido Dismutase/metabolismo , Fator de Necrose Tumoral alfa/metabolismoRESUMO
Acid (aspartyl), basic (arginyl) and neutral (alanyl) aminopeptidases degrade angiotensins, vasopressin, oxytocin, bradykinin and enkephalins. These peptides regulate memory, energy homeostasis, water-salt balance and blood pressure, functions that are mainly exerted in the hippocampus and hypothalamus, and that can be affected by diabetes mellitus. To evaluate the relationship between the diabetes mellitus and processing and inactivation roles of these representative aminopeptidases, we measured their activities in both brain structures of control and streptozotocin-diabetic rats. Hypothalamic soluble aspartyl and arginyl aminopeptidases presented significant decreased activity levels in diabetic rats, which were mitigated by insulin therapy. In addition to membrane-bound puromycin sensitive and insensitive alanyl aminopeptidases, its soluble puromycin sensitive form did not differ between diabetic and control rats in both brain structures. Glucose and/or insulin did not seem to alter in vitro the hypothalamic activities of soluble aspartyl and arginyl aminopeptidases. The implied hypothalamic control of regulatory peptide activity by aspartyl and arginyl aminopeptidases supports the hypothesis that the hydrolytic ability of these enzyme types could be a common link for the disruptions of water-salt balance, blood pressure and energy homeostasis in diabetes mellitus.
Assuntos
Aminopeptidases/metabolismo , Encefalopatias Metabólicas/enzimologia , Encefalopatias Metabólicas/etiologia , Diabetes Mellitus Experimental/complicações , Hipocampo/enzimologia , Hipotálamo/enzimologia , Aminopeptidases/análise , Animais , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/fisiologia , Encefalopatias Metabólicas/fisiopatologia , Antígenos CD13/análise , Antígenos CD13/metabolismo , Membrana Celular/efeitos dos fármacos , Membrana Celular/enzimologia , Regulação para Baixo/efeitos dos fármacos , Regulação para Baixo/fisiologia , Doenças do Sistema Endócrino/enzimologia , Doenças do Sistema Endócrino/etiologia , Doenças do Sistema Endócrino/fisiopatologia , Glutamil Aminopeptidase/análise , Glutamil Aminopeptidase/metabolismo , Hipocampo/fisiopatologia , Homeostase/fisiologia , Hipotálamo/fisiopatologia , Insulina/metabolismo , Insulina/farmacologia , Masculino , Neurônios/efeitos dos fármacos , Neurônios/enzimologia , Neuropeptídeos/metabolismo , Inibidores da Síntese de Proteínas/farmacologia , Puromicina/farmacologia , Ratos , Ratos Wistar , Equilíbrio Hidroeletrolítico/fisiologiaRESUMO
Although vitamin A has been reported to be essential to brain homeostasis, some central nervous system (CNS)-associated deleterious effects may be induced by vitamin A or by its metabolites. In this work, we investigated the effects of acute and chronic vitamin A supplementation at therapeutic (1,000 or 2,500 IU/kg/day) or excessive (4,500 or 9,000 IU/kg/day) doses on the redox state of the rat striatum. We found a 1.8- to 2.7-fold increase of lipid peroxidation in the striatum after acute or chronic supplementation (TBARS method). Therapeutic doses induced a 1.6- to 2.2-fold increase of protein carbonylation (dinitrophenylhydrazine (DNPH) derivatization). Vitamin A supplementation induced a 1.2- to 1.4-fold decrease of protein thiol content acutely and chronically. Superoxide dismutase (SOD) activity, assessed through the inhibition of epinephrine's autoxidation, was increased in a dose-dependent manner chronically. Acutely, both therapeutic and excessive vitamin A doses induced a 1.8- to 2.2-fold decrease of catalase (CAT) activity, as determined through the rate of decrease of hydrogen peroxide (H(2)O(2)). Glutathione peroxidase (GPx) activity did not change in this experimental model. Some vitamin A doses decreased the non-protein thiol content only chronically. Vitamin A supplementation decreased the striatal non-enzymatic antioxidant defenses (TRAP assay). Furthermore, our results show that vitamin A supplementation impaired the SOD/CAT ratio. Moreover, we observed a 1.6- to 2.0-fold decrease of locomotion and exploration in an open field after vitamin A supplementation. Therefore, our results suggest that vitamin A supplementation induces oxidative stress in the rat striatum and that it may be related to a metabolic impairment in such brain area.
Assuntos
Doenças dos Gânglios da Base/induzido quimicamente , Encefalopatias Metabólicas/induzido quimicamente , Corpo Estriado/efeitos dos fármacos , Discinesia Induzida por Medicamentos/fisiopatologia , Estresse Oxidativo/efeitos dos fármacos , Vitamina A/toxicidade , Animais , Antioxidantes/metabolismo , Doenças dos Gânglios da Base/metabolismo , Doenças dos Gânglios da Base/fisiopatologia , Encefalopatias Metabólicas/metabolismo , Encefalopatias Metabólicas/fisiopatologia , Catalase/efeitos dos fármacos , Catalase/metabolismo , Corpo Estriado/metabolismo , Corpo Estriado/fisiopatologia , Relação Dose-Resposta a Droga , Regulação para Baixo/efeitos dos fármacos , Regulação para Baixo/fisiologia , Esquema de Medicação , Comportamento Exploratório/efeitos dos fármacos , Comportamento Exploratório/fisiologia , Peroxidação de Lipídeos/efeitos dos fármacos , Peroxidação de Lipídeos/fisiologia , Masculino , Atividade Motora/efeitos dos fármacos , Atividade Motora/fisiologia , Oxirredução , Estresse Oxidativo/fisiologia , Carbonilação Proteica/efeitos dos fármacos , Carbonilação Proteica/fisiologia , Ratos , Ratos Wistar , Compostos de Sulfidrila/metabolismo , Superóxido Dismutase/efeitos dos fármacos , Superóxido Dismutase/metabolismo , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/fisiologiaRESUMO
BACKGROUND: The number of bariatric procedures is rapidly growing as the prevalence of obesity in the USA is increasing. Such procedures are not without complications, and those affecting the nervous system are often disabling and irreversible. We now describe our experience with these complications and review the pertinent literature. METHODS: We describe 26 patients with major neurologic conditions that seemed causally related to bariatric surgery encountered in the neurology service of a tertiary referral university medical center over a decade. RESULTS: The neurologic complications affected most regions of the nervous system: encephalopathy, optic neuropathy, myelopathy, polyradiculoneuropathy, and polyneuropathy. Myelopathy was the most frequent and disabling problem; symptoms began about a decade after surgery. Encephalopathy and polyradiculoneuropathy were acute and early complications. Except for vitamin B(12) and copper deficiencies in patients with myelopathy, we could not correlate specific nutritional deficiencies to the neurologic complications. All patients had multiple nutritional deficiencies, but their correction did not often yield dramatic results. The best result was achieved in one patient after surgical revision to reduce the bypassed jejunum. CONCLUSIONS: A wide spectrum of serious neurologic conditions may follow bariatric surgery. These complications may occur acutely or decades later.
Assuntos
Deficiência de Vitaminas/complicações , Encefalopatias Metabólicas/etiologia , Derivação Gástrica/efeitos adversos , Doenças Neurodegenerativas/etiologia , Obesidade Mórbida/cirurgia , Complicações Pós-Operatórias/etiologia , Adulto , Deficiência de Vitaminas/patologia , Deficiência de Vitaminas/fisiopatologia , Encéfalo/metabolismo , Encéfalo/patologia , Encéfalo/fisiopatologia , Encefalopatias Metabólicas/patologia , Encefalopatias Metabólicas/fisiopatologia , Cobre/deficiência , Suplementos Nutricionais/normas , Feminino , Derivação Gástrica/métodos , Humanos , Masculino , Pessoa de Meia-Idade , Doenças Neurodegenerativas/patologia , Doenças Neurodegenerativas/fisiopatologia , Obesidade Mórbida/fisiopatologia , Nervos Periféricos/metabolismo , Nervos Periféricos/patologia , Nervos Periféricos/fisiopatologia , Doenças do Sistema Nervoso Periférico/etiologia , Doenças do Sistema Nervoso Periférico/patologia , Doenças do Sistema Nervoso Periférico/fisiopatologia , Complicações Pós-Operatórias/patologia , Complicações Pós-Operatórias/fisiopatologia , Reoperação , Medula Espinal/metabolismo , Medula Espinal/patologia , Medula Espinal/fisiopatologia , Doenças da Medula Espinal/etiologia , Doenças da Medula Espinal/patologia , Doenças da Medula Espinal/fisiopatologia , Deficiência de Tiamina/etiologia , Deficiência de Tiamina/fisiopatologia , Deficiência de Vitamina B 12/etiologia , Deficiência de Vitamina B 12/fisiopatologia , Encefalopatia de Wernicke/etiologia , Encefalopatia de Wernicke/patologia , Encefalopatia de Wernicke/fisiopatologiaRESUMO
BACKGROUND: Segawa disease (autosomal dominant guanosine triphosphate cyclohydrolase I [GTP-I] deficiency, DYT5) is a hereditary dopa-responsive generalized dystonia. OBJECTIVE: To investigate the pathophysiologic mechanisms for dystonia in Segawa disease, we studied intracortical inhibition of the primary motor cortex in patients with Segawa disease. METHODS: We studied 9 patients with Segawa disease (8 genetically confirmed patients and 1 with abnormally low GTP-I activity) and 12 age-matched normal control subjects. We studied the active motor threshold (AMT) using single pulse transcranial magnetic stimulation (TMS) and the short-interval intracortical inhibition (SICI) of the motor cortex using the previously reported paired pulse TMS method. Responses were recorded from the first dorsal interosseous (FDI) and tibialis anterior (TA) muscles. RESULTS: The AMT was not significantly different between the patients and normal subjects. For both studied muscles, in Segawa disease, normal amount of SICI was evoked at interstimulus intervals (ISIs) of 1 to 4 msec even though they had dystonia in those muscles. CONCLUSION: Normal SICI of the motor cortex in Segawa disease stands in remarkable contrast to the previously reported reduction of SICI in focal dystonia. This suggests that the gamma-aminobutyric acid A system of the motor cortex is intact in Segawa disease. The pathophysiologic mechanisms for dystonia must be partly different between Segawa disease and focal dystonia.
Assuntos
Encefalopatias Metabólicas/fisiopatologia , Distúrbios Distônicos/fisiopatologia , Córtex Motor/fisiopatologia , Inibição Neural/genética , Vias Neurais/fisiopatologia , Ácido gama-Aminobutírico/metabolismo , Adulto , Gânglios da Base/metabolismo , Gânglios da Base/fisiopatologia , Biopterinas/análogos & derivados , Biopterinas/deficiência , Encefalopatias Metabólicas/diagnóstico , Encefalopatias Metabólicas/metabolismo , Diagnóstico Diferencial , Dopamina/metabolismo , Dopaminérgicos/farmacologia , Dopaminérgicos/uso terapêutico , Distúrbios Distônicos/diagnóstico , Distúrbios Distônicos/metabolismo , Potencial Evocado Motor/fisiologia , Feminino , GTP Cicloidrolase/deficiência , Humanos , Interneurônios/metabolismo , Levodopa/farmacologia , Levodopa/uso terapêutico , Masculino , Pessoa de Meia-Idade , Músculo Esquelético/inervação , Músculo Esquelético/fisiopatologia , Vias Neurais/metabolismo , Fenótipo , Estimulação Magnética TranscranianaRESUMO
BACKGROUND: Triphasic waves (TWs) and generalized nonconvulsive status epilepticus (GNCSE) share morphological features that may create diagnostic ambiguity. OBJECTIVE: To describe electroencephalographic differences between TWs and GNCSE. METHODS: We retrospectively compared the electroencephalograms (EEGs) of two groups of patients presenting with decreased level of consciousness; those with TWs associated with metabolic encephalopathy and those with GNCSE. We studied the following: demographics, etiology and EEG morphological features. All EEGs were classified blindly (TWs or GNCSE) by two expert EEGers. Agreement between experts and concordance with clinical diagnosis were measured. RESULTS: We analysed 87 EEGs (71 patients) with TWs and 27 EEGs (13 patients) with GNCSE. Agreement between experts and concordance with clinical diagnosis were excellent. When compared to TWs, epileptiform discharges associated with GNCSE had a higher frequency (mean=2.4Hz vs 1.8Hz) (p<0.001), a shorter duration of phase one (p=0.001), extra-spikes components (69% vs 0%) (p<0.001) and less generalized background slowing (15.1% vs 91.1%) (p<0.001). Amplitude predominance of phase two was common with TWs (40.8% vs 0%) (p=0.01). Lag of phase two was absent in all cases of GNCSE but present in 40.8% of patients with TWs. Noxious or auditory stimulation frequently increased the TWs (51%) while it had no effect on the epileptiform pattern (p=0.008). CONCLUSIONS: Certain EEG morphological criteria and the response to stimulation are very helpful in distinguishing TWs from GNCSE.
Assuntos
Córtex Cerebral/fisiopatologia , Eletroencefalografia/métodos , Epilepsia/diagnóstico , Epilepsia/fisiopatologia , Estado Epiléptico/diagnóstico , Estado Epiléptico/fisiopatologia , Estimulação Acústica , Potenciais de Ação/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Encefalopatias Metabólicas/diagnóstico , Encefalopatias Metabólicas/fisiopatologia , Diagnóstico Diferencial , Eletroencefalografia/normas , Humanos , Pessoa de Meia-Idade , Estimulação Física , Valor Preditivo dos Testes , Estudos RetrospectivosRESUMO
The purpose of the present study was to examine the role of histamine in the pathogenesis of experimental thiamine-deficient encephalopathy. By studying sagittal serial sections the authors were able to examine the topographical relationship between histamine-positive neurons and fibers, the number of mast cells, and localized lesions in the thalamus (TH) and inferior colliculus (IC). Adult rats were given a thiamine-deficient diet and pyrithiamine was given intraperitoneally (30 microg/100 g bodyweight per day), and the distribution of vulnerable regions and petechial bleeding was histologically examined by reconstruction of the sagittal serial sections. The distribution of mast cells and histamine-positive neurons and fibers was examined immunohistochemically in control rats, and compared between the vulnerable and non-vulnerable regions of the TH and tectum. Changes in the aforementioned measures during the thiamine-deficient state were also examined. The blood-brain barrier was examined using antibodies against rat endothelial barrier antigen (EBA) and albumin. The density of histamine-positive fibers in the vulnerable regions of the TH and IC was very low and not different from the non-vulnerable regions, and the number of mast cells was significantly higher in the lateral portion of the TH than the medial portion of the TH. The numbers of mast cells increased on days 7-10 after the start of the experiment, and significantly decreased on days 14-21. Histamine-positive neurons and fibers in the TH and IC also had the same changes. Bleeding of the IC occurred exclusively around arteries, and perivenous bleeding was absent. Albumin exudation and suppression of EBA expression of capillaries were found in the spongy lesions of the TH and IC. The role of histamine in selective vulnerability of the TH and IC in experimental thiamine-deficient encephalopathy was not supported. Findings in the present study suggest that the spongy change is a primary event, and vascular changes are secondary.
Assuntos
Encefalopatias Metabólicas/patologia , Colículos Inferiores/patologia , Mastócitos/patologia , Neurônios/patologia , Tálamo/patologia , Deficiência de Tiamina/patologia , Animais , Antimetabólitos/farmacologia , Barreira Hematoencefálica/efeitos dos fármacos , Barreira Hematoencefálica/fisiologia , Encefalopatias Metabólicas/etiologia , Encefalopatias Metabólicas/imunologia , Encefalopatias Metabólicas/fisiopatologia , Histamina/metabolismo , Imuno-Histoquímica , Colículos Inferiores/irrigação sanguínea , Colículos Inferiores/efeitos dos fármacos , Colículos Inferiores/imunologia , Masculino , Mastócitos/imunologia , Modelos Animais , Neurônios/imunologia , Neurônios/metabolismo , Piritiamina/farmacologia , Ratos , Ratos Sprague-Dawley , Tálamo/irrigação sanguínea , Tálamo/efeitos dos fármacos , Tálamo/imunologia , Tiamina/antagonistas & inibidores , Deficiência de Tiamina/complicações , Deficiência de Tiamina/imunologia , Deficiência de Tiamina/fisiopatologiaRESUMO
The dysregulation of membrane phospholipid metabolism exists throughout the body from the onset of psychosis in schizophrenic patients. This dysregulation is primarily due to altered contents of phospholipid bound EPUFAs, AA and DHA. These EPUFAs are highly enriched in the brain and are crucial for brain and behavioral development. A phospholipid metabolic defect may preexist the onset of psychosis, even through early embryonic stages. Because these membrane phospholipids play a crucial role in the membrane receptor-mediated signal transduction of several neuro-transmitters and growth factors, their altered metabolism may contribute to the reported abnormal information processing in schizophrenia. Severity of symptoms seems to correlate with the membrane AA and DHA status, which is influenced by patients' dietary intake and lifestyle. Such a metabolic defect can be prevented, however, and some membrane pathology can be corrected by dietary supplementation with a combination of AA and DHA and antioxidants such as vitamins E and C. In schizophrenia, it may be advisable to provide supplementation at the early stages of illness, when brain has a high degree of plasticity. Finally, at this time, supplementation has to be considered as an augmentation of conventional antipsychotic treatment.